Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients
10.1371/journal.pone.0054522
Saved in:
Main Authors: | Wang, L.-Z., Ramírez, J., Yeo, W., Chan, M.-Y.M., Thuya, W.-L., Lau, J.-Y.A., Wan, S.-C., Wong, A.L.-A., Zee, Y.-K., Lim, R., Lee, S.-C., Ho, P.C., Lee, H.-S., Chan, A., Ansher, S., Ratain, M.J., Goh, B.-C. |
---|---|
Other Authors: | CANCER SCIENCE INSTITUTE OF SINGAPORE |
Format: | Article |
Published: |
2014
|
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/110744 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1
by: Wang, L, et al.
Published: (2020) -
Influence of UGT1A9 intronic I399C>T polymorphism on SN-38 glucuronidation in Asian cancer patients
by: Sandanaraj, E., et al.
Published: (2011) -
UGT1A1 haplotype mutation among Asians in Singapore
by: Zhou, Y.Y., et al.
Published: (2016) -
Belinostat and panobinostat (HDACI): In vitro and in vivo studies in thyroid cancer
by: Chan, D., et al.
Published: (2014) -
A sensitive and specific liquid chromatography-tandem mass spectrometric method for determination of belinostat in plasma from liver cancer patients
by: Wang, L.-Z., et al.
Published: (2014)